(NASDAQ: GPCR) Structure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.87%.
Structure Therapeutics's earnings in 2026 is -$210,685,000.On average, 16 Wall Street analysts forecast GPCR's earnings for 2026 to be -$324,036,801, with the lowest GPCR earnings forecast at -$399,598,666, and the highest GPCR earnings forecast at -$273,322,429. On average, 12 Wall Street analysts forecast GPCR's earnings for 2027 to be -$357,640,078, with the lowest GPCR earnings forecast at -$488,794,797, and the highest GPCR earnings forecast at -$303,903,960.
In 2028, GPCR is forecast to generate -$172,676,428 in earnings, with the lowest earnings forecast at -$322,889,993 and the highest earnings forecast at $301,992,614.